FDA's Data Falsification Proposed Rule Is Overly Strict, Sponsors Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency needs to better define the evidence threshold for reporting suspected clinical trial fraud to the agency, industry commenters say.